Shares of Organogenesis Holdings fell to a 52-week low after the regenerative medicine company reported second-quarter results that showed a sharp revenue decline and wider-than-expected losses, while cutting its full-year outlook.

Shares of the company were recently down 33% at $1.61.

Organogenesis posted a second-quarter net loss of $96.3 million, or 77 cents a share, compared with a loss of $9.4 million, or 10 cents a share, a year earlier.

Revenue fell 58% to $42.8 million from $100.8 million a year earlier. The decline was driven by a 61% drop in Advanced Wound Care revenue to $36.1 million.

The company now expects full-year revenue of $179 million to $215 million, representing a decline of 62% to 68% from 2025 revenue of $564.2 million. The updated forecast is weaker than its previous outlook, which called for a 45% to 52% year-over-year revenue decline.

Chief Executive Gary Gillheeney said the company saw "measured improvement" in business trends during the second quarter but that the recovery from the market contraction was progressing more slowly than expected. He said the company expects its evidence-based regenerative medicine products to drive market share gains as the market resets.

Organogenesis also disclosed it entered into an at-the-market equity offering program that allows the company to sell up to $75 million of shares, potentially diluting existing shareholders.